BiologicalDrug
Alveltamig clinical trials
Also written ZG006.
- studies test it
- 10
- open now
- 10
- in phase 3
- 2
- first study started
- 2023
Keep track of what changes. Save the Alveltamig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ZG006
- 10
Studies by the year they started
10 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Alveltamig is read from its arms, and is right about nine times in ten.
Testing it · 10
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06283719Written as ZG006
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07595913Written as ZG006
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07231445Written as ZG006
- Study of ZGGS34 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07258121Written as ZG006
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05978284Written as ZG006
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07038096Written as ZG006
- Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerRecruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07189455Written as ZG006
- A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06592638Written as ZG006
- Study of ZG006 in Participants With Neuroendocrine Prostate CancerNot yet recruitingPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07024277Written as ZG006
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06440057Written as ZG006